SARS-CoV-2 variants of concern (VOC) B.1.1.7 (alpha) and B.1.351 (beta) show increased transmissibility and enhanced antibody neutralization resistance. Here we demonstrate in K18-hACE2 transgenic mice that B.1.1.7 and B.1.351 are 100-fold more lethal than the original SARS-CoV-2 bearing 614D. B.1.1.7 and B.1.351 cause more severe organ lesions in K18-hACE2 mice than early SARS-CoV-2 strains bearing 614D or 614G, with B.1.1.7 and B.1.351 infection resulting in distinct tissue-specific cytokine signatures, significant D-dimer depositions in vital organs and less pulmonary hypoxia signaling before death. However, K18-hACE2 mice with prior infection of early SARS-CoV-2 strains or intramuscular immunization of viral spike or receptor binding domain are resistant to the lethal reinfection of B.1.1.7 or B.1.351, despite having reduced neutralization titers against these VOC than early strains. Our results thus distinguish pathogenic patterns in K18-hACE2 mice caused by B.1.1.7 and B.1.351 infection from those induced by early SARS-CoV-2 strains, and help inform potential medical interventions for combating COVID-19.
Malaria,
one of the most common vector borne human diseases, is a major world
health issue. In 2015 alone, more than 200 million people were infected
with malaria, out of which, 429 000 died. Even though artemisinin-based
combination therapies (ACT) are highly effective at treating malaria
infections, novel efforts toward development of vaccines to prevent
transmission are still needed. Pfs25, a postfertilization stage parasite
surface antigen, is a leading transmission-blocking vaccine (TBV)
candidate. It is postulated that Pfs25 anchors to the cell membrane
using a glycosylphosphatidylinositol (GPI) linker, which itself possesses
pro-inflammatory properties. In this study, Escherichia coli derived extract (XtractCF+TM) was used in cell free protein
synthesis [CFPS] to successfully express >200 mg/L of recombinant
Pfs25 with a C-terminal non-natural amino acid (nnAA), namely, p-azidomethyl phenylalanine (pAMF), which possesses a reactive
azide group. Thereafter, a unique conjugate vaccine (CV), namely,
Pfs25-GPI was generated with dibenzocyclooctyne (DBCO) derivatized
glycan core of malaria GPI using a simple but highly efficient copper
free click chemistry reaction. In mice immunized with Pfs25 or Pfs25-GPI,
the Pfs25-GPI group showed significantly higher titers compared to
the Pfs25 group. Moreover, only purified IgGs from Pfs25-GPI group
were able to significantly block transmission of parasites to mosquitoes,
as judged by a standard membrane feeding assay [SMFA]. To our knowledge,
this is the first report of the generation of a CV using Pfs25 and
malaria specific GPI where the GPI is shown to enhance the ability
of Pfs25 to elicit transmission blocking antibodies.
SARS-CoV-2 continues to circulate globally resulting in emergence of several variants of concern (VOC), including B.1.1.7 and B.1.351 that show increased transmissibility and enhanced resistance to antibody neutralization. In a K18-hACE2 transgenic mouse model, we demonstrate that Both B.1.1.7 and B.1.351 are 100 times more lethal than the original SARS-CoV-2 bearing 614D. Mice infected with B.1.1.7 and B.1.351 exhibited more severe lesions in internal organs than those infected with early SARS-CoV-2 strains bearing 614D or 614G. Infection of B.1.1.7 and B.1.351 also results in distinct tissue-specific cytokine signatures, significant D-dimer depositions in vital organs and less pulmonary hypoxia signaling before death as compared to the mice infected with early SARS-CoV-2 strains. However, K18-hACE2 mice with the pre-existing immunity from prior infection or immunization were resistant to the lethal reinfection of B.1.1.7 or B.1.351, despite having reduced neutralization titers against these VOC. Our study reveals distinguishing pathogenic patterns of B.1.1.7 and B.1.351 variants from those early SARS-CoV-2 strains in K18-hACE2 mice, which will help to inform potential medical interventions for combating COVID-19.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.